-
Mashup Score: 25New York medical school eliminates tuition after $1bn gift - 2 month(s) ago
The record-breaking donation came from a 93-year-old former professor, who is the widow of a wealthy investor.
Source: www.bbc.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 70FDA approves capivasertib with fulvestrant for breast cancer - 6 month(s) ago
On November 16, 2023, the Food and Drug Administration approved capivasertib (Truqap, AstraZeneca Pharmaceuticals) with fulvestrant for breast cancer.
Source: www.fda.govCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 68FDA approves capivasertib with fulvestrant for breast cancer - 6 month(s) ago
On November 16, 2023, the Food and Drug Administration approved capivasertib (Truqap, AstraZeneca Pharmaceuticals) with fulvestrant for breast cancer.
Source: www.fda.govCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 68FDA approves capivasertib with fulvestrant for breast cancer - 6 month(s) ago
On November 16, 2023, the Food and Drug Administration approved capivasertib (Truqap, AstraZeneca Pharmaceuticals) with fulvestrant for breast cancer.
Source: www.fda.govCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 68FDA approves capivasertib with fulvestrant for breast cancer - 6 month(s) ago
On November 16, 2023, the Food and Drug Administration approved capivasertib (Truqap, AstraZeneca Pharmaceuticals) with fulvestrant for breast cancer.
Source: www.fda.govCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 68FDA approves capivasertib with fulvestrant for breast cancer - 6 month(s) ago
On November 16, 2023, the Food and Drug Administration approved capivasertib (Truqap, AstraZeneca Pharmaceuticals) with fulvestrant for breast cancer.
Source: www.fda.govCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 68FDA approves capivasertib with fulvestrant for breast cancer - 6 month(s) ago
On November 16, 2023, the Food and Drug Administration approved capivasertib (Truqap, AstraZeneca Pharmaceuticals) with fulvestrant for breast cancer.
Source: www.fda.govCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 2
Seagen Inc. (Nasdaq: SGEN) today announced that the Phase 3 HER2CLIMB-02 clinical trial of TUKYSA® (tucatinib) in combination with the antibody-drug c
Source: www.businesswire.comCategories: Latest Headlines, Oncologists1Tweet
-
Mashup Score: 0
22nd Annual International Congress on the Future of Breast Cancer® East.
Source: event.gotoper.comCategories: Latest Headlines, Oncologists1Tweet
-
Mashup Score: 0
Ad hoc announcement pursuant to Art. 53 LR Ad hoc announcement pursuant to Art. 53 LR Novartis is a global healthcare company based in Switzerland that provides solutions to address the evolving needs of patients worldwide.
Source: NovartisCategories: Hem/Oncs, Latest HeadlinesTweet
New York medical school eliminates tuition after $1bn gift - What a fantastic way to give back! #diversity #inclusion #affordable. Nicely done Dr Ruth Gottesman! https://t.co/RUoJiRoYGn